New laser could spark hair regrowth in balding patients
NCT ID NCT05460611
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests a 1470nm laser on 10 adults with androgenetic alopecia (common baldness) or scarring alopecia. Researchers will measure hair density and counts using imaging, and track satisfaction. The goal is to see if the laser is safe and can improve hair growth.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 1470nm non-ablative laser
- What this could lead to
- If it works, this could offer a new, non-drug option to improve hair density in people with common or scarring hair loss.
- What could go wrong
- This is a very small pilot study with only 10 people, so results may not apply to everyone. The laser may not work or could cause side effects like skin irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 10 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2023
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for hair loss * Subject must voluntarily sign and date an IRB approved informed consent form * Subjects with diagnosis of biopsy proven androgenetic alopecia or scarring alopecia with hair loss recorded over the past 6 months * Subjects must have a stable hair loss treatment regimen with a plateau in results for at least 3 months * Able to read, understand and voluntarily provide written informed consent * Subject is determined to be healthy, non-smoker who agrees not to make any changes to their daily hair treatment regimen during the study * Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements * Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period Exclusion Criteria: * Subject does not have the capacity to consent to the study * Subject has other types of alopecia of the scalp like alopecia areata * History of intralesional steroid injections to the scalp in the last 12 months * Pregnant women * Any medical condition that in the consideration of the investigator, would present an increased risk of a photosensitivity reaction to the subject * Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months * Allergy or history of prior reaction to lidocaine * History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months * History or current use of the following prescription medications: i. Immunosuppressive medications/biologics, 6 months prior to and during the study ii. Accutane or other systemic retinoids within the past twelve months * Smoking or vaping in the past 12 months * History of uncontrolled hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders * History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Androgenetic alopecia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Montefiore Einstein Advanced Care
RECRUITINGElmsford, New York, 10523, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a scalp gel turn back male pattern baldness?
- Can a Four-Times-a-Year injection regrow hair in men?
- Can exosome shots outperform minoxidil for baldness?
- Can tiny needles boost hair growth in balding men?
- A battle for your hair: herbal oil vs. minoxidil serum in a Head-to-Head trial
- Can light boost PRP's power against hair loss?